99 related articles for article (PubMed ID: 35993)
1. Suicidal risk in the treatment of outpatient schizophrenics with long-acting neuroleptics.
Niturad A; Nicholschi-Oproiu L
Agressologie; 1978; 19(C):145-8. PubMed ID: 35993
[No Abstract] [Full Text] [Related]
2. [Prophylactic efficacy of long-acting vs. short-acting neuroleptics in schizophrenic out-patients (author's transl)].
Tegeler J; Lehmann E; Stockschlaeder M
Nervenarzt; 1980 Nov; 51(11):654-61. PubMed ID: 6109262
[No Abstract] [Full Text] [Related]
3. [Depot neuroleptics in social psychiatric practice].
Pruss U; Rose HK; Zechner A
Psychiatr Prax; 1984 Jul; 11(4):101-8. PubMed ID: 6148764
[TBL] [Abstract][Full Text] [Related]
4. [Considerations on the use of long-acting neuroleptics in a mental health center].
Carotti P; Merli R
Minerva Med; 1986 Sep; 77(34-35):1577-83. PubMed ID: 2876402
[TBL] [Abstract][Full Text] [Related]
5. [Experience with long acting psychopharmaceutics in psychiatric hospitals].
Reimer F
Int Pharmacopsychiatry; 1974; 9(4):245-7. PubMed ID: 4156352
[No Abstract] [Full Text] [Related]
6. Eleven years of experience with depot neuroleptics.
Gross H; Kaltenbäck E; Pfolz H
Acta Psychiatr Belg; 1981; 81(2):128-32. PubMed ID: 6117183
[TBL] [Abstract][Full Text] [Related]
7. [The psychoprophylactic importance of treatment with depot neuroleptics in schizophrenia].
Chiriţă V; Stanciu J; Pirozynski T
Rev Med Chir Soc Med Nat Iasi; 1989; 93(3):497-500. PubMed ID: 2576888
[TBL] [Abstract][Full Text] [Related]
8. Experience with depot neuroleptics in ambulatory practice.
Fiolet J
Acta Psychiatr Belg; 1981; 81(2):182-8. PubMed ID: 6117188
[TBL] [Abstract][Full Text] [Related]
9. [Role of long-acting neuroleptics in the treatment of schizophrenia].
Levine J; Schooler NR; Cassano G
Encephale; 1979; 5(3):285-90. PubMed ID: 39740
[TBL] [Abstract][Full Text] [Related]
10. Advantages and disadvantages of depot-neuroleptics as maintenance medication for chronic schizophrenics.
Möller HJ; Kissling W
Clin Neuropharmacol; 1986; 9 Suppl 4():259-62. PubMed ID: 2882841
[No Abstract] [Full Text] [Related]
11. An atypical long-acting injectable antipsychotic: implications for pharmacotherapy of schizophrenia.
Dursun S
J Psychopharmacol; 2005 Sep; 19(5 Suppl):3-4. PubMed ID: 16144780
[No Abstract] [Full Text] [Related]
12. [Experiences with depot-neuroleptics in an after-care unit. Organization of the therapy exemplified with pipotiazine palmitate].
Salvesen C; Vaksdal K
Tidsskr Nor Laegeforen; 1973 Aug; 93(24):1699-703. PubMed ID: 4149082
[No Abstract] [Full Text] [Related]
13. [5 years' experience with prolonged-action neuroleptics].
Lopez-Ibor Aliño JM; Tabares Pujante J
Actas Luso Esp Neurol Psiquiatr Cienc Afines; 1973; 1(5):721-31. PubMed ID: 4150175
[No Abstract] [Full Text] [Related]
14. Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics.
Lindenmayer JP; Eerdekens E; Berry SA; Eerdekens M
J Clin Psychiatry; 2004 Aug; 65(8):1084-9. PubMed ID: 15323593
[TBL] [Abstract][Full Text] [Related]
15. [Long-term treatment of outpatients with depot neuroleptics (author's transl)].
Saameli W
Schweiz Rundsch Med Prax; 1981 Feb; 70(6):206-10. PubMed ID: 6113584
[No Abstract] [Full Text] [Related]
16. Depot neuroleptics: side effects and safety.
Marder SR
J Clin Psychopharmacol; 1986 Feb; 6(1 Suppl):24S-29S. PubMed ID: 2870089
[TBL] [Abstract][Full Text] [Related]
17. Clinical experience with pipothiazine palmitate (19552 R.P.) in hospitalized and open ward patients with functional psychoses.
Salvesen C; Vaksdal K
Behav Neuropsychiatry; 1973 Oct-1974 Mar; 5(7-12):3-7. PubMed ID: 4154740
[No Abstract] [Full Text] [Related]
18. Strategies for improving compliance in treatment of schizophrenia by using a long-acting formulation of an antipsychotic: clinical studies.
Kane JM
J Clin Psychiatry; 2003; 64 Suppl 16():34-40. PubMed ID: 14680417
[TBL] [Abstract][Full Text] [Related]
19. [The first long-acting atypical antipsychotic: new milestone in the treatment of schizophrenia].
Faludi G
Neuropsychopharmacol Hung; 2005 Mar; 7(1):22-7. PubMed ID: 16167464
[TBL] [Abstract][Full Text] [Related]
20. [The risk of rehospitalisation during therapy with atypical and typical neuroleptics--a contribution to differential indication].
Müller P; Nerenz H; Schaefer E
Psychiatr Prax; 2002 Oct; 29(7):388-91. PubMed ID: 12378421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
